1-16 of 16
Todd M. Pitts
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Phase II Study of Potentiation of Pembrolizumab with Binimetinib and Bevacizumab in Refractory Microsatellite-Stable Colorectal Cancer

Robert W. Lentz, Tyler J. Friedrich, Patrick J. Blatchford, Kimberly R. Jordan, Todd M. Pitts, Hannah R. Robinson, S. Lindsey Davis, Sunnie S. Kim, Alexis D. Leal, Mathew R. Lee, Meredith R.N. Waring, Anne C. Martin, Adrian T.A. Dominguez, Stacey M. Bagby, Sarah J. Hartman, S. Gail Eckhardt, Wells A. Messersmith, Christopher H. Lieu
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (17): 3768–3778.
https://doi.org/10.1158/1078-0432.CCR-24-0090
Published: 03 September 2024
View article titled, A Phase II Study of Potentiation of Pembrolizumab with Binimetinib and Bevacizumab in Refractory Microsatellite-Stable Colorectal Cancer
Open the PDF for A Phase II Study of Potentiation of Pembrolizumab with Binimetinib and Bevacizumab in Refractory Microsatellite-Stable Colorectal Cancer in another window
Includes: Supplementary data
Journal Articles

Preclinical and Dose-Finding Phase I Trial Results of Combined Treatment with a TORC1/2 Inhibitor (TAK-228) and Aurora A Kinase Inhibitor (Alisertib) in Solid Tumors

S. Lindsey Davis, Anastasia A. Ionkina, Stacey M. Bagby, James D. Orth, Brian Gittleman, Joshua M. Marcus, Elaine T. Lam, Bradley R. Corr, Cindy L. O'Bryant, Ashley E. Glode, Aik-Choon Tan, Jihye Kim, John J. Tentler, Anna Capasso, Kyrie L. Lopez, Daniel L. Gustafson, Wells A. Messersmith, Stephen Leong, S. Gail Eckhardt, Todd M. Pitts, Jennifer R. Diamond
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (17): 4633–4642.
https://doi.org/10.1158/1078-0432.CCR-19-3498
Published: 01 September 2020
View article titled, Preclinical and Dose-Finding Phase I Trial Results of Combined Treatment with a TORC1/2 Inhibitor (TAK-228) and Aurora A Kinase Inhibitor (Alisertib) in Solid Tumors
Open the PDF for Preclinical and Dose-Finding Phase I Trial Results of Combined Treatment with a TORC1/2 Inhibitor (TAK-228) and Aurora A Kinase Inhibitor (Alisertib) in Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Pancreatic Tumor Microenvironment Modulation by EphB4-ephrinB2 Inhibition and Radiation Combination

Shelby Lennon, Ayman Oweida, Dallin Milner, Andy V. Phan, Shilpa Bhatia, Benjamin Van Court, Laurel Darragh, Adam C. Mueller, David Raben, Jorge L. Martínez-Torrecuadrada, Todd M. Pitts, Hilary Somerset, Kimberly R. Jordan, Kirk C. Hansen, Jason Williams, Wells A. Messersmith, Richard D. Schulick, Philip Owens, Karyn A. Goodman, Sana D. Karam
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (11): 3352–3365.
https://doi.org/10.1158/1078-0432.CCR-18-2811
Published: 03 June 2019
View article titled, Pancreatic Tumor Microenvironment Modulation by EphB4-ephrinB2 Inhibition and Radiation Combination
Open the PDF for Pancreatic Tumor Microenvironment Modulation by EphB4-ephrinB2 Inhibition and Radiation Combination in another window
Includes: Supplementary data
Journal Articles

Abstract PR03: Characterizing the immune context of responses to immunotherapy in humanized patient derived xenograft models of CRC

Anna Capasso, Julie Lang, Todd M. Pitts, S. Lindsey Davis, Chris H. Lieu, Stacey M. Bagby, Aik Choon Tan, John J. Tentler, Jill E. Slansky, Roberta Pelanda, S. Gail Eckhardt
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (16_Supplement): PR03.
https://doi.org/10.1158/1557-3265.PDX16-PR03
Published: 15 August 2016
View article titled, Abstract PR03: Characterizing the immune context of responses to immunotherapy in humanized patient derived xenograft models of CRC
Journal Articles

Imaging endpoints to predict response to IGF1R/IR inhibition in CRC models

Natalie J. Serkova, Erica L. Bradshaw-Pierce, Kendra M. Hasebroock, Andrea L. Merz, Todd M. Pitts, Gail S. Eckhardt
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (19_Supplement): PR9.
https://doi.org/10.1158/DIAG-10-PR9
Published: 15 August 2014
View article titled, Imaging endpoints to predict response to IGF1R/IR inhibition in CRC models
Journal Articles

Imaging end-points to predict response to IGF1R/IR inhibition in CRC models

Natalie J. Serkova, Erica L. Bradshaw-Pierce, Kendra M. Hasebroock, Andrea L. Merz, Todd M. Pitts, Gail S. Eckhardt
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (19_Supplement): A14.
https://doi.org/10.1158/DIAG-10-A14
Published: 15 August 2014
View article titled, Imaging end-points to predict response to IGF1R/IR inhibition in CRC models
Journal Articles

Overcoming IGF1R/IR Resistance through Inhibition of MEK Signaling in Colorectal Cancer Models

Sara A. Flanigan, Todd M. Pitts, Timothy P. Newton, Gillian N. Kulikowski, Aik Choon Tan, Martine C. McManus, Anna Spreafico, Maria I. Kachaeva, Heather M. Selby, John J. Tentler, S. Gail Eckhardt, Stephen Leong
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (22): 6219–6229.
https://doi.org/10.1158/1078-0432.CCR-13-0145
Published: 14 November 2013
View article titled, Overcoming IGF1R/IR Resistance through Inhibition of MEK Signaling in Colorectal Cancer Models
Open the PDF for Overcoming IGF1R/IR Resistance through Inhibition of MEK Signaling in Colorectal Cancer Models in another window
Includes: Supplementary data
Journal Articles

Rational Combination of a MEK Inhibitor, Selumetinib, and the Wnt/Calcium Pathway Modulator, Cyclosporin A, in Preclinical Models of Colorectal Cancer

Anna Spreafico, John J. Tentler, Todd M. Pitts, Aik Choon Tan, Mark A. Gregory, John J. Arcaroli, Peter J. Klauck, Martine C. McManus, Ryan J. Hansen, Jihye Kim, Lindsey N. Micel, Heather M. Selby, Timothy P. Newton, Kelly L. McPhillips, Daniel L. Gustafson, James V. DeGregori, Wells A. Messersmith, Robert A. Winn, S. Gail Eckhardt
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (15): 4149–4162.
https://doi.org/10.1158/1078-0432.CCR-12-3140
Published: 31 July 2013
View article titled, Rational Combination of a MEK Inhibitor, Selumetinib, and the Wnt/Calcium Pathway Modulator, Cyclosporin A, in Preclinical Models of Colorectal Cancer
Open the PDF for Rational Combination of a MEK Inhibitor, Selumetinib, and the Wnt/Calcium Pathway Modulator, Cyclosporin A, in Preclinical Models of Colorectal Cancer in another window
Includes: Supplementary data
Journal Articles

Abstract A46: Tumor P-glycoprotein Correlates with Efficacy of PF-03758309 Against In Vitro and In Vivo models of Colorectal Cancer

Erica L. Bradshaw-Pierce, Todd M. Pitts, Kelly L. McPhillips, Daniel L. Gustafson, Aik-Choon Tan, Leslie Nguyen, Mark West, Timothy Fisher, Brion W. Murray, S. Gail Eckhardt
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (10_Supplement): A46.
https://doi.org/10.1158/1078-0432.MECHRES-A46
Published: 04 March 2013
View article titled, Abstract A46: Tumor P-glycoprotein Correlates with Efficacy of PF-03758309 Against In Vitro and In Vivo models of Colorectal Cancer
Open the PDF for Abstract A46: Tumor P-glycoprotein Correlates with Efficacy of PF-03758309 Against In Vitro and In Vivo models of Colorectal Cancer in another window
Journal Articles

Predictive Biomarkers of Sensitivity to the Aurora and Angiogenic Kinase Inhibitor ENMD-2076 in Preclinical Breast Cancer Models

Jennifer R. Diamond, S. Gail Eckhardt, Aik Choon Tan, Timothy P. Newton, Heather M. Selby, Kelsey L. Brunkow, Maria I. Kachaeva, Marileila Varella-Garcia, Todd M. Pitts, Mark R. Bray, Graham C. Fletcher, John J. Tentler
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (1): 291–303.
https://doi.org/10.1158/1078-0432.CCR-12-1611
Published: 02 January 2013
View article titled, Predictive Biomarkers of Sensitivity to the Aurora and Angiogenic Kinase Inhibitor ENMD-2076 in Preclinical Breast Cancer Models
Open the PDF for Predictive Biomarkers of Sensitivity to the Aurora and Angiogenic Kinase Inhibitor ENMD-2076 in Preclinical Breast Cancer Models in another window
Includes: Supplementary data
Journal Articles

Common PIK3CA Mutants and a Novel 3′ UTR Mutation Are Associated with Increased Sensitivity to Saracatinib

John J. Arcaroli, Kevin S. Quackenbush, Rebecca W. Powell, Todd M. Pitts, Anna Spreafico, Marileila Varella-Garcia, Lynne Bemis, Aik Choon Tan, Jaclyn M. Reinemann, Basel M. Touban, Arvind Dasari, S. Gail Eckhardt, Wells A. Messersmith
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (9): 2704–2714.
https://doi.org/10.1158/1078-0432.CCR-11-3167
Published: 30 April 2012
View article titled, Common PIK3CA Mutants and a Novel 3′ UTR Mutation Are Associated with Increased Sensitivity to Saracatinib
Open the PDF for Common PIK3CA Mutants and a Novel 3′ UTR Mutation Are Associated with Increased Sensitivity to Saracatinib in another window
Includes: Supplementary data
Journal Articles

Preclinical Activity of the Rational Combination of Selumetinib (AZD6244) in Combination with Vorinostat in KRAS-Mutant Colorectal Cancer Models

M. Pia Morelli, John J. Tentler, Gillian N. Kulikowski, Aik-Choon Tan, Erica L. Bradshaw-Pierce, Todd M. Pitts, Amy M. Brown, Sujatha Nallapareddy, John J. Arcaroli, Natalie J. Serkova, Manuel Hidalgo, Fortunato Ciardiello, S. Gail Eckhardt
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (4): 1051–1062.
https://doi.org/10.1158/1078-0432.CCR-11-1507
Published: 14 February 2012
View article titled, Preclinical Activity of the Rational Combination of Selumetinib (AZD6244) in Combination with Vorinostat in KRAS-Mutant Colorectal Cancer Models
Open the PDF for Preclinical Activity of the Rational Combination of Selumetinib (AZD6244) in Combination with Vorinostat in KRAS-Mutant Colorectal Cancer Models in another window
Includes: Supplementary data
Journal Articles

Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of ENMD-2076, a Novel Angiogenic and Aurora Kinase Inhibitor,in Patients with Advanced Solid Tumors

Jennifer R. Diamond, Bruno R. Bastos, Ryan J. Hansen, Daniel L. Gustafson, S. Gail Eckhardt, Eunice L. Kwak, Shuchi S. Pandya, Graham C. Fletcher, Todd M. Pitts, Gillian N. Kulikowski, Mark Morrow, Jamie Arnott, Mark R. Bray, Carolyn Sidor, Wells Messersmith, Geoffrey I. Shapiro
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (4): 849–860.
https://doi.org/10.1158/1078-0432.CCR-10-2144
Published: 15 February 2011
View article titled, Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of ENMD-2076, a Novel Angiogenic and Aurora Kinase Inhibitor,in Patients with Advanced Solid Tumors
Open the PDF for Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of ENMD-2076, a Novel Angiogenic and Aurora Kinase Inhibitor,in Patients with Advanced Solid Tumors in another window
Includes: Supplementary data
Journal Articles

The Insulin-like Growth Factor I Receptor/Insulin Receptor Tyrosine Kinase Inhibitor PQIP Exhibits Enhanced Antitumor Effects in Combination with Chemotherapy Against Colorectal Cancer Models

Sara A. Flanigan, Todd M. Pitts, S. Gail Eckhardt, John J. Tentler, Aik Choon Tan, Andrew Thorburn, Stephen Leong
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (22): 5436–5446.
https://doi.org/10.1158/1078-0432.CCR-10-2054
Published: 14 November 2010
View article titled, The Insulin-like Growth Factor I Receptor/Insulin Receptor Tyrosine Kinase Inhibitor PQIP Exhibits Enhanced Antitumor Effects in Combination with Chemotherapy Against Colorectal Cancer Models
Open the PDF for The Insulin-like Growth Factor I Receptor/Insulin Receptor Tyrosine Kinase Inhibitor PQIP Exhibits Enhanced Antitumor Effects in Combination with Chemotherapy Against Colorectal Cancer Models in another window
Journal Articles

Development of an Integrated Genomic Classifier for a Novel Agent in Colorectal Cancer: Approach to Individualized Therapy in Early Development

Todd M. Pitts, Aik Choon Tan, Gillian N. Kulikowski, John J. Tentler, Amy M. Brown, Sara A. Flanigan, Stephen Leong, Christopher D. Coldren, Fred R. Hirsch, Marileila Varella-Garcia, Christopher Korch, S. Gail Eckhardt
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (12): 3193–3204.
https://doi.org/10.1158/1078-0432.CCR-09-3191
Published: 14 June 2010
View article titled, Development of an Integrated Genomic Classifier for a Novel Agent in Colorectal Cancer: Approach to Individualized Therapy in Early Development
Open the PDF for Development of an Integrated Genomic Classifier for a Novel Agent in Colorectal Cancer: Approach to Individualized Therapy in Early Development in another window
Includes: Supplementary data
Journal Articles

Assessment of the In vivo Antitumor Effects of ENMD-2076, a Novel Multitargeted Kinase Inhibitor, against Primary and Cell Line–Derived Human Colorectal Cancer Xenograft Models

John J. Tentler, Erica L. Bradshaw-Pierce, Natalie J. Serkova, Kendra M. Hasebroock, Todd M. Pitts, Jennifer R. Diamond, Graham C. Fletcher, Mark R. Bray, S. Gail Eckhardt
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (11): 2989–2998.
https://doi.org/10.1158/1078-0432.CCR-10-0325
Published: 31 May 2010
View article titled, Assessment of the <em>In vivo</em> Antitumor Effects of ENMD-2076, a Novel Multitargeted Kinase Inhibitor, against Primary and Cell Line–Derived Human Colorectal Cancer Xenograft Models
Open the PDF for Assessment of the <em>In vivo</em> Antitumor Effects of ENMD-2076, a Novel Multitargeted Kinase Inhibitor, against Primary and Cell Line–Derived Human Colorectal Cancer Xenograft Models in another window